Carlos Diaz, MD
Gastroenterology · Miami, FLNPI 1881012557
Payments from drug & device makers
Across 380 payments — averaging $79.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$20K
- AbbVie$2K
- Bristol Myers Squibb$2K
- Johnson & Johnson$2K
- QOL Medical, LLC$814
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$416
- plus $3K from 29 others
What the payments were for
- Consulting fees$4,77516%
- Speaking & faculty fees$15,05350%
- Travel & lodging$1,5395%
- Food & beverage$8,69729%
- Education$1851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 11 | $20,425 |
| AbbVie | 96 | $2,348 |
| Bristol Myers Squibb | 22 | $1,727 |
| Johnson & Johnson(2 entities) | 77 | $1,721 |
| QOL Medical, LLC | 45 | $814 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $416 |
| Ardelyx, Inc. | 17 | $373 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $332 |
| Janssen Scientific Affairs, LLC | 2 | $233 |
| Fujifilm Healthcare Americas Corporation | 1 | $172 |
| Gilead | 3 | $167 |
| Teva Pharmaceuticals USA, Inc. | 2 | $139 |
| Glaukos Corporation | 2 | $114 |
| Echosens North America, Inc. | 1 | $114 |
| Braintree Laboratories, Inc. | 6 | $110 |
| Nestle Healthcare Nutrition Inc. | 5 | $101 |
| Regeneron Healthcare Solutions, Inc. | 5 | $100 |
| Redhill Biopharma Inc. | 6 | $98 |
| Pfizer | 4 | $86 |
| Phathom Pharmaceuticals, Inc. | 5 | $78 |
| Ironwood Pharmaceuticals, Inc | 3 | $70 |
| Sanofi | 3 | $70 |
| Lilly USA, LLC | 3 | $69 |
| Organon | 3 | $54 |
| Merck | 2 | $44 |
| Celltrion USA Inc. | 2 | $39 |
| Novo Nordisk | 2 | $37 |
| Evoke Pharma, Inc. | 2 | $32 |
| Ipsen Biopharmaceuticals, Inc | 1 | $31 |
| Madrigal Pharmaceuticals | 1 | $31 |
| Exact Sciences | 1 | $24 |
| Intercept Pharmaceuticals, Inc. | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,249 in reported general payments places this provider in the 80th percentile of 1,388 gastroenterology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 36 | $110,636 |
| Humira(Cf) PenAdalimumab | 11 | $74,681 |
| LinzessLinaclotide | 85 | $54,163 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 71 | $12,059 |
| Mesalamine | 14 | $6,149 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 89 | $5,929 |
| Mesalamine ErMesalamine | 14 | $4,136 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 22 | $3,597 |
| Dexlansoprazole DrDexlansoprazole | 17 | $3,305 |
| Omeprazole | 330 | $3,146 |
| Famotidine | 137 | $1,728 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 12 | $1,488 |
| Esomeprazole Magnesium | 16 | $896 |
| SuprepSodium, Potassium,mag Sulfates | 14 | $892 |
| Sucralfate | 47 | $849 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $2,348 | $164,799121 claims |
| Braintree Laboratories, Inc.Sutab, Suflave | $110 | $5,08534 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,388 gastroenterology providers in Florida.
Other gastroenterology in Miami
- Zaid RanaMiami$5.4M
- Angel VentoMiami$2.5M
- Francisco Bautista-MenaMiami$2M
- Miguel RodriguezMiami$2M
- Frances Robles-PenaMiami$1.7M
- Javier SobradoMiami$1.4M
- David KermanMiami$1.4M
- Lukasz KwapiszMiami$1.3M
- Oriana DamasMiami$903K
- David GoldbergMiami$858K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.